A clinical trial of cephaloridine.
Cephaloridine, a cephalosporin derivative, was administered to 30 selected patients, including 19 with moderate to severe impairment of renal function. This antibiotic eradicated infections due to Staphylococcus pyogenes, and urinary tract infections due to a single member of the species Escherichia coli or Aerobacter aerogenes, which were sensitive to the drug on bacteriological testing. The drug failed in mixed urinary tract infections.No adverse effects were observed except for the development of superinfection in patients with urinary tract infections. No allergic reactions were noted in 10 patients who had reported previous reactions to penicillin.From these studies in patients with renal disease, approximations can be made concerning dose requirements in these special cases. Because of the apparent absence of dose-related toxic effects in humans, cephaloridine was particularly useful in the treatment of patients with renal disease and infections due to susceptible bacteria.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001996:Bronchopneumonia / Q000188:drug therapy*; D002481:Cellulitis / Q000188:drug therapy*; D002509:Cephaloridine / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D002764:Cholecystitis / Q000188:drug therapy*; D003556:Cystitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010309:Parotitis / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy*
D002511:Cephalosporins; D002509:Cephaloridine